Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 12/12/2018
SIETES contiene 92610 citas

 1 a 20 de 65 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018;74:1061-70. [Ref.ID 102823]
2. Cita con resumen
Mørch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med 2017;377:2228-39. [Ref.ID 102165]
3. Cita con resumen
Tricco AC, Thomas SM, Veroniki AA, Hamid JS, Cogo E, Strifler L, Khan PA, Robson R, Sibley KM, MacDonald H, Riva JJ, Thavorn K, Wilson C, Holroyd-Leduc J, Kerr GD, Feldman F, Majumdar SR, Jaglal SB, Hui W, Straus SE. Comparisons of interventions for preventing falls in older adults. A systematic review and meta-analysis. JAMA 2017;318:1687-99. [Ref.ID 102139]
4. Cita con resumen
Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. JAMA 2016;315:2415-23. [Ref.ID 100421]
5. Cita con resumen
Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]
6. Cita con resumen
Chiu WY, Chien JY, Yang WS, Juanq JM, Lee JJ, Tsai KS. The risk of osteonecrosis of the jaws in Taiwanese osteoporotic patients treated with oral alendronate or raloxifene.. J Clin Endocrinol Metab 2014;99:2729-35. [Ref.ID 97859]
7. Cita con resumen
Anónimo. Thalidomide: risk of second primary malignancies. Drug Safety Update 2013;6:mayo. [Ref.ID 95524]
8. Cita con resumen
Khong TP, de Vries F, Goldenberg JSB, Klungel OH, Ronbison NJ, Ibáñez L, Petri H. Potential impact of benzodiazepine use on the rate of hip fractures in five large European Countries and the United States. Calcif Tissue Int 2013;91:24-31. [Ref.ID 94615]
9. Cita con resumen
Bolland MJ, Grey A. Data openness. Reporting of absolute risk. BMJ 2010;341:1063. [Ref.ID 89685]
11. Cita con resumen
Wheeler BW, Metcalfe C, Gunnell D, Stephens P, Martin RM. Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological study. Br J Clin Pharmacol 2009;68:752-64. [Ref.ID 87165]
12. Cita con resumen
Vaithianathan R, Hockey PM, Moore TJ, Bates DW. Iatrogenic effects of COX-2 inhibitors in the US population: findings from the Medical Expenditure Panel Survey. Drug Saf 2009;32:335-43. [Ref.ID 85765]
Anónimo. Understanding statistical terms: 2. Drug Ther Bull 2009;47:35-6. [Ref.ID 85453]
14. Cita con resumen
Anónimo. Déclaration d'Helsinki de l'Association médicale mondiale. Prescrire 2008;28:570-3. [Ref.ID 83797]
15. Cita con resumen
Graciani A, Zuluaga-Zuluaga MC, Banegas JR, León-Muñoz LM, de la Cruz JJ, Rodríguez-Artalejo F. Mortalidad cardiovascular atribuible a la presión arterial en la población española de 50 años o más. Med Clin (Barc) 2008;131:125-9. [Ref.ID 83554]
17. Cita con resumen
Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D, for the Million Women Study Collaboration. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134-9. [Ref.ID 81669]
19.Tiene citas relacionadas Cita con resumen
Sasieni P. Cervical cancer prevention and hormonal contraception. Lancet 2007;370:1591-2. [Ref.ID 81472]
20. Cita con resumen
Anónimo. Merck & Co's Arcoxia soundly rejected by US FDA panel. Scrip 2007;3251:23. [Ref.ID 79813]
Seleccionar todas
 1 a 20 de 65 siguiente >>